Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

allogeneic interleukin-17-producing CD8-positive T cells

A preparation of allogeneic human cytotoxic T lymphocytes that express the pro-inflammatory cytokine interleukin-17 (IL-17; IL17), with potential immunomodulating and anti-tumor activities. Upon ex vivo stimulation, the IL-17-producing CD8-positive T cells (Tc17) convert to interferon-gamma (IFNg; IFN-g)-producing CD8-positive T cells (Tc1). Tc1 cells exert enhanced anti-tumor cytotoxicity. Human Tc17 cells may contribute to a number of human inflammatory and malignant diseases.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	allogeneic IL-17-producing CD8+ T cells allogeneic IL-17+ CD8 T cells allogeneic Tc17 cells

allogeneic interleukin-17-producing CD8-positive T cells

Search NCI's Drug Dictionary